The method of producing lysozyme

 

(57) Abstract:

Usage: biotechnology, food industry and medical industry. The inventive liquefied protein fraction of egg add 0.6 to 1.4% ammonia solution. The selection of lysozyme is carried out by sorption carried out by sequential passage through the sorbent silagra brand SH-SV, pre-balanced starting solvent, which is used as 0.6 to 1.4% ammonia solution , the protein solution and again starting solvent with subsequent elution of lysozyme mixture of 0.8 to 2.0% solution of acetic acid with 0.1-0.3 M sodium chloride, after which the solution of lysozyme are concentrating on hollow fibers. 70 L,

 

Same patents:

FIELD: food industry.

SUBSTANCE: invention is related to poultry-processing industry. The method envisages separation of egg albumen from yolk, stirring albuminous mass, addition of an acid, heat treatment of the albuminous mixture and pasterurisation of the albumen product. The acid is represented by citric, lactic or malic acid or a mixture of these acids in an amount of 1.0 - 6.0% (by weight) in the form of a 5% water solution till the albuminous mixture pH is 4.5-6.1. Heat treatment of the albuminous mixture is implemented during 1-3 minutes till temperature is 60-70°C; then one separates the liquid phase. Then the coagulate is pasteurised at a temperature of 80-90°C during 10-20 minutes.

EFFECT: invention allows to preserve native properties of egg albumen and enhance the product quality.

1 tbl

FIELD: food industry.

SUBSTANCE: method involves preliminary heating of native whole egg proteins at a temperature no more than 65°C during 2 - 15 minutes. The first stage of hydrolysis is performed using the first protease chosen from the group containing Bacillus amyloliquefaciens and Bacillus licheniformis bacterial proteases and their mixtures, trypsin and pancreatin. One performs an intermediate heating stage whereat the first hydrolysis product is heated up to a temperature no more than 75°C. The second stage of hydrolysis is performed using the second protease chosen from the group containing Bacillus licheniformis bacterial proteases, Aspergillus oryzae fungous proteases, trypsin and pancreatin and one proceeds with an inactivation stage whereat the second hydrolysis product is heated up to 85-90°C and maintained at this temperature during 30 minutes. Optionally Aspergillus oryzae fungous protease may be added in an amount of 10 - 60% during the intermediate heating stage; the Aspergillus oryzae fungous protease remainder is added after the intermediate heating stage.

EFFECT: invention allows to manufacture hypoallergenic proteins of whole egg.

3 cl, 2 dwg, 6 ex

FIELD: food industry.

SUBSTANCE: invention relates to food industry. The food composition for usage in food products for phenylketonuric children includes a dry egg product - 5-30 wt % in terms of dry substance and swelling maize starch - 70-95 wt % in terms of dry substance.

EFFECT: introduction of the food composition with an egg protein product into dishes recipes enhances the product nutritious value, has an immune-stimulating effect, allows to dose phenylalanine in alimentation of phenylketonuric children.

2 cl, 2 tbl, 3 ex

FIELD: food industry.

SUBSTANCE: invention relates to food industry. The product contains whey proteins -15÷20, egg protein - 10÷12, dry beestings - 4÷7, L-glutamine amino acid -1÷5, fructose - 6÷10, vegetal food fibres complex represented by a mixture of gum arabic and fructooligosaccharides taken at a weight ratio of (30-70):(70-30) 1÷5, creatine monohydrate - 3÷5, vitamin premix - 0.12÷0.15, mineral premix - 2.02÷2.05, flavouring additives - 0.48÷0.62 and maltodextrin - up to 100. The ratio of initial components is expressed in terms of wt %.

EFFECT: invention allows to manufacture a product with enhanced nutritive value, intensified anticatabolic, immunomodulating, detoxification and lipid-mobilising properties.

4 cl, 3 ex

FIELD: medicine.

SUBSTANCE: invention relates to a preparation containing fertilised eggs, a method of its preparation and application. Preparation of eggs includes a mixture of yolk and protein extracted from fertilised eggs, incubated for a period of time from 18 to 36 hours. Said mixture of yolk and protein is characterised by such ratio, in compliance with which protein content is equal to 2 vol% to 40 vol%. Method for producing preparation of eggs involves incubation of fertilised eggs for a period of time from 18 hours to 36 hours; selection of certain amount of yolk and a certain amount of protein from incubated fertilised eggs obtained at previous step, in such proportion that protein quantity ranges from 2 vol% to 40 vol% of volume of yolk; homogenised yolk and protein and sharp cooling of preparation of eggs. Invention also discloses a functional food product, a dietary supplement, pharmaceutical, veterinary and cosmetic composition containing said preparation of eggs. Disclosed is use of said preparation of eggs as a cosmetic agent for skin care, as well as hair or fur. Also disclosed is use of preparation of eggs for preparing a drug for treating acute or chronic pain in case of conditions associated with pain; for treating degenerative diseases and conditions associated with inflammation.

EFFECT: invention enables to obtain a preparation of eggs with high regenerative, analgesic and anti-inflammatory properties.

19 cl, 12 dwg, 11 ex

FIELD: biotechnology, microbiology.

SUBSTANCE: invention relates to the microorganism strain Klebsiella pneumoniae GISK № 278 isolated from a patent feces suffering from intestine dysbacteriosis. The strain is used for preparing an agent for producing the lysozyme inhibitor. The level of activity of lysozyme inhibitor produced by this strain is 1.64-2.16 mcg/ml of *OD value.

EFFECT: valuable properties of strain.

1 tbl, 2 ex

FIELD: chemistry; biochemistry.

SUBSTANCE: present invention pertains to biochemistry. To obtain lysozyme enzyme and avidin protein from albumen, chromatography of albumen homogenisate is carried out on silochrome C-80 at neutral pH (7.0-7.5). Ballast proteins are removed in a 0.2 M glycine - NaOH buffer in the presence of 0.3 M NaCl at pH 9.3-9.5. Target proteins are eluted together with carbonate buffer with 0.5-0.8 M NaCl, with pH 10.8-11.0, and subsequent separation of proteins through gel filtration on a column with sephadex G-75.

EFFECT: simplification of the method of obtaining electrophoretically pure proteins and increasing the efficiency of the method.

1 dwg, 4 ex

FIELD: medicine.

SUBSTANCE: invention relates to composition, which contains Arthrospira maxima subjected to physiological stress, for application as biocide and/or therapeutic medication. Invention also relates to method of prevention or treatment of infection or contamination of subject with organism, where method includes stage of introduction of efficient amount of composition, containing Arthrospira maxima subjected to physiological stress, to subject.

EFFECT: increase of efficiency of biocidal compositions and therapeutic preparations.

30 cl, 34 dwg, 23 tbl, 13 ex

FIELD: medicine.

SUBSTANCE: method provides phagocyte recovery from a cell mixture. The recovered cells are mixed with medium 199 in 18 bottles, and the cells are attached to glass at room temperature for 60 minutes. In 9 bottles, a culture medium containing medium 199, L-glutamine and mixed human serum heated for 30 min at 52°C is added to the cells in the preset amounts to produce cell samples. A culture medium of said composition containing 0.01% of zymosan particles is added to another 9 bottles with the cells to produce the cell samples. The prepared cell samples are divided into three portions. One one-third potion of zymosan and zymosan-free samples are frozen. The second portion of the zymosan and zymosan-free cell samples are cultivated at temperature 37°C for 4 to 6 h to be frozen, and the third portion of the zymosan and zymosan-free samples are cultivated at temperature 37°C for 18 to 24 h to be frozen respectively. All 18 bottles are exposed to simultaneous multiple freezing to -10°C and thawing at room temperature to complete recovery of intracellular lysozyme with determination of amount by a micromethod and calculation of synthesised lysozyme and a phagocyte activation value (PAV) by formula: PAV=Z Lsynth - Z-free Lsynth, mcg/ml, where Z Lsynth is a difference of lysozyme amount in the cultivated zymosan cells and lysozyme amount in the uncultivated zymosan cells, mcg/ml; Z-free Lsynth is a difference of lysozyme amount in the cultivated zymosan-free cells and lysozyme amount in the uncultivated zymosan-free cells, mcg/ml; the phagocyte activation value for long-term activation mechanism assessment is calculated by said formula by results of cell cultivation for 4 to 6 hours, and the phagocyte activation value for long-term activation mechanism assessment is calculated by said formula by results of cell cultivation for 18 to 24 hours.

EFFECT: invention allows more precise phagocyte activation assessment.

4 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of biotechnology. Claimed is protein, including catalytic fragment of sialidase and possessing sialidase activity, which is selected from protein, whose sequence includes amino acids 274-666, or 274-681, or 290-666, or 290-681 SEQ ID NO:12, or includes amino acid sequence SEQ ID NO:14, described herein. Described is fused protein, which includes described above protein and anchor domain. Also given is information about molecules of nucleic acids, which code said proteins, expression vectors, containing said nucleic acids, and pharmaceutical compositions, containing said protein or fusion protein. Claimed is method of treatment or prevention of viral infection, caused by virus of influenza or parainfluenza, including application of therapeutically efficient amount of said composition to epithelial cells of subject.

EFFECT: invention makes it possible to extend arsenal of means against infection, caused by influenza or parainfluenza vitus.

25 cl, 2 tbl, 13 dwg, 17 ex

FIELD: food industry.

SUBSTANCE: additive is produced from wheat offal fermented with mould fungi. The additive agents are at least one ferment and a mixture of nutritional ingredients for yeast: ergosterol, N-acetylglucosamine, vitamins, nucleic acids and amino acids. The said additive is also used for activation of alcohol fermentation or pre-fermentation intended for preparation of yeast under aerobic conditions.

EFFECT: reduction of the simultaneous saccharification-fermentation stage time in the process of ethanol production, increase of yeast growth and efficiency.

21 cl, 2 dwg, 4 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to biochemistry and provides a pharmaceutical composition for treating Gaucher's disease, which contains as an active ingredient lyophilised plant cells which express recombinant human glucocerebrosidase, a pharmaceutically acceptable carrier, where said pharmaceutical composition is intended for oral administration and where said human glucocerebrosidase has high-mannose glycosylation.

EFFECT: invention enables to obtain an effective pharmaceutical composition for treating Gaucher's disease with high enzyme biological activity owing to high-mannose glycosylation thereof.

16 cl, 21 dwg, 3 tbl, 6 ex

FIELD: biotechnology.

SUBSTANCE: an isolated polypeptide having a lysozyme activity is presented. Isolated polynucleotide coding the said polypeptide is presented. Compositions for extraction of bacterial genomic DNA, composition of animal feed and animal feed supplement, containing the said polypeptide, are presented. This is the method for extracting DNA out of bacteria using the said polypeptide. An expression vector of a nucleic acid containing the said polynucleotide operably linked to regulatory sequences is presented. A recombinant bacteria or fungus host cell is introduced for producing the said polypeptide. It comprises of the said polynucleotide operably linked to regulatory sequences. A method for producing a polypeptide having lysozyme activity using the said host cells is presented.

EFFECT: group of inventions allows to obtain a lysozymic enzyme with an improved thermal stability, using which makes it possible to avoid a loss of enzyme activity at production stages combined with temperature exposure.

20 cl, 6 dwg, 15 tbl, 13 ex

Up!